Top

Published in:

01-07-2014 | Key Review Article

Cytokines in Common Variable Immunodeficiency as Signs of Immune Dysregulation and Potential Therapeutic Targets – A Review of the Current Knowledge

Authors: Farnaz Najmi Varzaneh, Bärbel Keller, Susanne Unger, Asghar Aghamohammadi, Klaus Warnatz, Nima Rezaei

Published in: Journal of Clinical Immunology | Issue 5/2014

Abstract

Common variable immunodeficiency (CVID) is characterized by low levels of circulating immunoglobulins and compromised specific antibody response leading to frequent infections. Cytokines play an important role in the orchestration of the antibody response. Several previous studies have attempted to identify distinct cytokines responsible for the inflammatory changes and different manifestations of CVID, but there are conflicting results regarding the cytokine profiles in CVID patients. In light of this, an extensive review regarding the level of various cytokines and their potential therapeutic role in CVID patients was performed. This review delineates the contribution of interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-21, interferons, tumor necrosis factor (TNF)-α, IL-17, APRIL (a proliferation inducing ligand) and BAFF (B cell activating factor) in CVID disease and outline their potential therapeutic implications in these patients.

Cunningham-Rundles C, Kazbay K, Zhou Z, Mayer L. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency. J Interferon Cytokine Res. 1995;15(3):269–76.PubMed

Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92 (1):34–48. Epub 1999/07/22. doi: 10.1006/clim.1999.4725 S1521-6616 (99) 94725-3 [pii]. PubMed PMID: 10413651.

Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep. 2001;1(5):421–9. Epub 2002/03/15. PubMed PMID: 11892068

Seppanen M, Aghamohammadi A, Rezaei N. Is there a need to redefine the diagnostic criteria for common variable immunodeficiency? Expert Rev Clin Immunol. 2014;10(1):1–5. doi:10.1586/1744666X.2014.870478.PubMed

Saiki O, Ralph P, Cunningham-Rundles C, Good RA. Three distinct stages of B-cell defects in common varied immunodeficiency. Proc Natl Acad Sci U S A. 1982;79(19):6008–12.PubMedCentralPubMed

Cunningham-Rundles C, Radigan L, Knight AK, Zhang L, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J Immunol. 2006;176(3):1978–87.PubMed

Holm AM, Aukrust P, Aandahl EM, Muller F, Tasken K, Froland SS. Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency–involvement of protein kinase A type I. J Immunol. 2003;170(11):5772–7.PubMed

Borte S, Pan-Hammarstrom Q, Liu C, Sack U, Borte M, Wagner U, et al. Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood. 2009;114(19):4089–98. doi:10.1182/blood-2009-02-207423.PubMed

Di Renzo M, Serrano D, Zhou Z, George I, Becker K, Cunningham-Rundles C. Enhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS. Clin Exp Immunol. 2001;125 (1):117–22. Epub 2001/07/27. doi: cei1560 [pii]. PubMed PMID: 11472434; PubMed Central PMCID: PMC1906110.

10.

Fischer MB, Wolf HM, Hauber I, Eggenbauer H, Thon V, Sasgary M, et al. Activation via the antigen receptor is impaired in T cells, but not in B cells from patients with common variable immunodeficiency. Eur J Immunol. 1996;26(1):231–7. doi:10.1002/eji.1830260136.PubMed

11.

Fiedler W, Sykora KW, Welte K, Kolitz JE, Cunningham-Rundles C, Holloway K, et al. T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clin Immunol Immunopathol. 1987;44(2):206–18.PubMed

12.

Di Renzo M, Zhou Z, George I, Becker K, Cunningham-Rundles C. Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation. Clin Exp Immunol. 2000;120 (3):503–11. Epub 2000/06/09. doi: cei1239 [pii]. PubMed PMID: 10844530; PubMed Central PMCID: PMC1905559.

13.

North ME, Webster AD, Farrant J. Defects in proliferative responses of T cells from patients with common variable immunodeficiency on direct activation of protein kinase C. Clin Exp Immunol. 1991;85(2):198–201.PubMedCentralPubMed

14.

North ME, Spickett GP, Allsop J, Webster AD, Farrant J. Defective DNA synthesis by T cells in acquired 'common-variable' hypogammaglobulinaemia on stimulation with mitogens. Clin Exp Immunol. 1989;76(1):19–23.PubMedCentralPubMed

15.

Sneller MC, Strober W. Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J Immunol. 1990;144(10):3762–9.PubMed

16.

Aukrust P, Muller F, Froland SS. Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes. Clin Immunol Immunopathol. 1994;70 (3):217–24. Epub 1994/03/01. doi: S0090122984710324 [pii]. PubMed PMID: 7906214.

17.

Kruger G, Welte K, Ciobanu N, Cunningham-Rundles C, Ralph P, Venuta S, et al. Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol. 1984;4(4):295–303.PubMed

18.

Jaffe JS, Eisenstein E, Sneller MC, Strober W. T-cell abnormalities in common variable immunodeficiency. Pediatr Res. 1993;33 (1 Suppl):S24-7; discussion S7-8. Epub 1993/01/01. doi: 10.1203/00006450-199305001-00128. PubMed PMID: 7679486.

19.

Stagg AJ, Funauchi M, Knight SC, Webster AD, Farrant J. Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 1994;96(1):48–53.PubMedCentralPubMed

20.

Kondratenko I, Amlot PL, Webster AD, Farrant J. Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells. MRC Immunodeficiency Group. Clin Exp Immunol. 1997;108(1):9–13. Epub 1997/04/01. PubMed PMID: 9097904; PubMed Central PMCID: PMC1904616

21.

Oliva A, Scala E, Quinti I, Paganelli R, Ansotegui IJ, Giovannetti A, et al. IL-10 production and CD40L expression in patients with common variable immunodeficiency. Scand J Immunol. 1997;46(1):86–90.PubMed

22.

Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A. 1994;91(3):1099–103.PubMedCentralPubMed

23.

Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Galicier L, Lepelletier Y, Webster D, et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood. 2004;104 (8):2441–3. Epub 2004/07/01. doi: 10.1182/blood-2004-04-1325 2004-04-1325 [pii]. PubMed PMID: 15226176.

24.

Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52. doi:10.1038/32588.PubMed

25.

McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005;79 (1):17–27. Epub 2004/12/15. doi: 79/1/17 [pii] 10.1128/JVI.79.1.17-27.2005. PubMed PMID: 15596797; PubMed Central PMCID: PMC538703.

26.

Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2004;103 (4):1391–7. Epub 2003/10/11. doi: 10.1182/blood-2003-06-1959 2003-06-1959 [pii]. PubMed PMID: 14551144.

27.

Rogge L. A genomic view of helper T cell subsets. Ann N Y Acad Sci. 2002;975:57–67.PubMed

28.

Rezaei N, Aghamohammadi A, Kardar GA, Nourizadeh M, Pourpak Z. T- helper 1 and 2 cytokine assay in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2008;18(6):449–53.PubMed

29.

Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol. 2004;114 (6):1265–73; quiz 74. Epub 2004/12/04. doi: S0091674904026429 [pii] 10.1016/j.jaci.2004.10.019. PubMed PMID: 15577820.

30.

Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252(1):104–15. doi:10.1111/imr.12028.PubMedCentralPubMed

31.

Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. 2012;209(7):1241–53. doi:10.1084/jem.20120994.PubMedCentralPubMed

32.

Rezaei N, Aghamohammadi A, Shakiba Y, Mahmoudi M, Jalali A, Moradi B, et al. Cytokine gene polymorphisms in common variable immunodeficiency. Int Arch Allergy Immunol. 2009;150 (1):1–7. Epub 2009/04/03. doi: 000210374 [pii] 10.1159/000210374. PubMed PMID: 19339796.

33.

Ishida H. [Clinical implication of IL-10 in patients with immune and inflammatory diseases]. Rinsho Byori. 1994;42 (8):843–52. Epub 1994/08/01. PubMed PMID: 7933621.

34.

Briere F, Bridon JM, Chevet D, Souillet G, Bienvenu F, Guret C, et al. Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. J Clin Invest. 1994;94(1):97–104. doi:10.1172/JCI117354.PubMedCentralPubMed

35.

Zielen S, Bauscher P, Hofmann D, Meuer SC. Interleukin 10 and immune restoration in common variable immunodeficiency. Lancet. 1993;342 (8873):750–1. Epub 1993/09/18. doi: 0140-6736 (93) 91746-9 [pii]. PubMed PMID: 8103865.

36.

Pastorelli G, Roncarolo MG, Touraine JL, Peronne G, Tovo PA, de Vries JE. Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) produce reduced levels of interleukin-4, interleukin-2 and interferon-gamma, but proliferate normally upon activation by mitogens. Clin Exp Immunol. 1989;78(3):334–40.PubMedCentralPubMed

37.

Ferrer JM, Iglesias J, Hernandez M, Matamoros N. Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients. Clin Exp Immunol. 1995;102(2):286–9.PubMedCentralPubMed

38.

Fischer MB, Hauber I, Vogel E, Wolf HM, Mannhalter JW, Eibl MM. Defective interleukin-2 and interferon-gamma gene expression in response to antigen in a subgroup of patients with common variable immunodeficiency. The Journal of allergy and clinical immunology. 1993;92(2):340–52. PubMed PMID: 8349943

39.

Eisenstein EM, Jaffe JS, Strober W. Reduced interleukin-2 (IL-2) production in common variable immunodeficiency is due to a primary abnormality of CD4+ T cell differentiation. J Clin Immunol. 1993;13(4):247–58.PubMed

40.

Ibanez C, Sune P, Fierro A, Rodriguez S, Lopez M, Alvarez A, et al. Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia. BioDrugs. 2005;19(1):59–65.PubMed

41.

Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8(15):1314–25.PubMed

42.

Bankers-Fulbright JL, Kalli KR, McKean DJ. Interleukin-1 signal transduction. Life Sci. 1996;59(2):61–83.PubMed

43.

Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. doi:10.1182/blood-2010-07-273417.PubMedCentralPubMed

44.

Rezaei N, Amirzargar AA, Shakiba Y, Mahmoudi M, Moradi B, Aghamohammadi A. Proinflammatory cytokine gene single nucleotide polymorphisms in common variable immunodeficiency. Clin Exp Immunol. 2009;155 (1):21–7. Epub 2008/12/17. doi: CEI3790 [pii] 10.1111/j.1365-2249.2008.03790.x. PubMed PMID: 19076825; PubMed Central PMCID: PMC2665675.

45.

Zielen S, Dengler TJ, Bauscher P, Meuer SC. Defective CD2 T cell pathway activation in common variable immunodeficiency (CVID). Clin Exp Immunol. 1994;96(2):253–9.PubMedCentralPubMed

46.

Trujillo CM, Muskus C, Arango J, Patino PJ, Montoya CJ. Quantitative and functional evaluation of innate immune responses in patients with common variable immunodeficiency. Journal of investigational allergology & clinical immunology. 2011;21(3):207–15. PubMed PMID: 21548449

47.

Haveman LM, Scherrenburg J, Maarschalk-Ellerbroek LJ, Hoek PD, Schuurman R, de Jager W, et al. T-cell response to viral antigens in adults and children with common variable immunodeficiency and specific antibody deficiency. Clin Exp Immunol. 2010;161(1):108–17. doi:10.1111/j.1365-2249.2010.04159.x.PubMedCentralPubMed

48.

Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4856):1169–76.PubMed

49.

Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett. 2007;114(1):1–8. doi:10.1016/j.imlet.2007.08.005.PubMedCentralPubMed

50.

Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5 (179):179ra43. doi: 10.1126/scitranslmed.3005265. PubMed PMID: 23552371; PubMed Central PMCID: PMC3686517.

51.

Isgro A, Marziali M, Mezzaroma I, Luzi G, Mazzone AM, Guazzi V, et al. Bone marrow clonogenic capability, cytokine production, and thymic output in patients with common variable immunodeficiency. J Immunol. 2005;174(8):5074–81.PubMed

52.

Inoue Y, Kondo N, Motoyoshi F, Inoue R, Orii T. Interleukin-2 and interferon-gamma production by peripheral blood lymphocytes of patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 1994;4(3):122–5.PubMed

53.

Giovannetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol. 2007;178(6):3932–43.PubMed

54.

Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis. 2011;17(1):251–9. doi:10.1002/ibd.21376.PubMedCentralPubMed

55.

Pons J, Ferrer JM, Martinez-Pomar N, Iglesias-Alzueta J, Matamoros N. Costimulatory molecules and cytokine production by T lymphocytes in common variable immunodeficiency disease. Scand J Immunol. 2006;63(5):383–9. doi:10.1111/j.1365-3083.2006.01753.x.PubMed

56.

Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L. Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2. N Engl J Med. 1994;331(14):918–21. doi:10.1056/NEJM199410063311405.PubMed

57.

Cunningham-Rundles C, Mayer L, Sapira E, Mendelsohn L. Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2. Clin Immunol Immunopathol. 1992;64(1):46–56.PubMed

58.

Cunningham-Rundles C, Bodian C, Ochs HD, Martin S, Reiter-Wong M, Zhuo Z. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol. 2001;100(2):181–90. doi:10.1006/clim.2001.5052.PubMed

59.

Rump JA, Jahreis A, Schlesier M, Stecher S, Peter HH. A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 1997;110(2):167–73. PubMed Central PMCID: PMC2265503.PubMedCentralPubMed

60.

Bergstedt-Lindqvist S, Moon HB, Persson U, Moller G, Heusser C, Severinson E. Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE. Eur J Immunol. 1988;18(7):1073–7. doi:10.1002/eji.1830180716.PubMed

61.

Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66–70.PubMedCentralPubMed

62.

Rezaei N, Haji-Molla-Hoseini M, Aghamohammadi A, Pourfathollah AA, Moghtadaie M, Pourpak Z. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J Clin Immunol. 2008;28(1):78–84. doi:10.1007/s10875-007-9135-6.PubMed

63.

Thon V, Wolf HM, Sasgary M, Litzman J, Samstag A, Hauber I, et al. Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients. Clin Exp Immunol. 1997;110(2):174–81.PubMedCentralPubMed

64.

Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, et al. Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Cienc. 2004;76 (4):707–26. Epub 2004/11/24. doi: S0001-37652004000400007 [pii]/S0001-37652004000400007. PubMed PMID: 15558152.

65.

Agondi RC, Barros MT, Rizzo LV, Kalil J, Giavina-Bianchi P. Allergic asthma in patients with common variable immunodeficiency. Allergy. 2010;65(4):510–5. doi:10.1111/j.1398-9995.2009.02211.x.PubMed

66.

Agondi RC, Barros MT, Kokron CM, Cohon A, Oliveira AK, Kalil J, et al. Can patients with common variable immunodeficiency have allergic rhinitis? American journal of rhinology & allergy. 2013;27(2):79–83. doi: 10.2500/ajra.2013.27.3855. PubMed PMID: 2356219

67.

Borte S, Lanig H, Borte M, Fasshauer M, Sack U. Therapeutic implications of the IL-21: IL-4 receptor system in children with common variable immunodeficiency syndrome. Klin Padiatr. 2010;222(6):362–7. doi:10.1055/s-0030-1265207.PubMed

68.

Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, et al. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 1993;363(6425):172–6.PubMed

69.

Del Vecchio GC, Martire B, Lassandro G, Cecinati V, De Mattia D, Ciccarelli M, et al. Reduced interleukin-5 production by peripheral CD4+ T cells in common variable immunodeficiency patients. Immunopharmacol Immunotoxicol. 2008;30(4):679–86. doi:10.1080/08923970802278102.PubMed

70.

Smith CI, Moller G, Severinson E, Hammarstrom L. Frequencies of interleukin-5 mRNA-producing cells in healthy individuals and in immunoglobulin-deficient patients, measured by in situ hybridization. Clin Exp Immunol. 1990;81(3):417–22.PubMedCentralPubMed

71.

Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101(2):311–20. doi:10.1172/JCI1368.PubMedCentralPubMed

72.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–88. doi:10.1016/j.bbamcr.2011.01.034.PubMed

73.

Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5. doi:10.1002/eji.201040391.PubMed

74.

Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse 3rd HC, Goldschmidt H, et al. IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood. 2010;115(9):1746–54. doi:10.1182/blood-2009-08-237941.PubMedCentralPubMed

75.

Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994;53(8):521–4.PubMedCentralPubMed

76.

Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991;147(1):117–23. Epub 1991/07/01. PubMed PMID: 2051017

77.

Ishihara K, T H. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13 ((4–5)):357–68.

78.

T H. Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86 (7):717–30.

79.

Ueland T, Froland SS, Bollerslev J, Aukrust P. Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency. Eur J Clin Investig. 2001;31(1):72–8. PubMed PMID: 11168441.

80.

Hong R, Agrawal S, Gollapudi S, Gupta S. Impaired pneumovax-23-induced monocyte-derived cytokine production in patients with common variable immunodeficiency. J Clin Immunol. 2010;30(3):435–41. doi:10.1007/s10875-010-9371-z.PubMed

81.

Pandolfi F, Paganelli R, Cafaro A, Oliva A, Giovannetti A, Scala E, et al. Abnormalities of lymphocyte subpopulations in CVI do not correlate with increased production of IL-6. Immunodeficiency. 1993;4(1–4):19–23.PubMed

82.

vd Heyden-Rynsch BF, Diener C, Vogelsang H, Jager L. [In vitro IL-6- and immunoglobulin-production in patients with variable immunodeficiency syndrome (CVID)]. Immunitat und Infektion. 1993;21 Suppl 1:43–4. PubMed PMID: 8344691.

83.

van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(2):113–9.PubMedCentralPubMed

84.

Kikuchi K, Kasai H, Watanabe A, Lai AY, Kondo M. IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression. J Immunol. 2008;181(1):383–92.PubMedCentralPubMed

85.

Dias S, Silva Jr H, Cumano A, Vieira P. Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. J Exp Med. 2005;201(6):971–9. doi:10.1084/jem.20042393.PubMedCentralPubMed

86.

Appasamy PM. Interleukin-7 and lymphopoiesis: biological and clinical implications. Cancer Treat Res. 1995;80:235–60.PubMed

87.

Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. The Journal of experimental medicine. 1994;180(5):1955–60. PubMed PMID: 7964471; PubMed Central PMCID: PMC2191751

88.

Johnson SE, Shah N, Panoskaltsis-Mortari A, LeBien TW. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J Immunol. 2005;175(11):7325–31.PubMed

89.

Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7(1):73–9. doi:10.1038/83381.PubMed

90.

Ponchel F, Cuthbert RJ, Goeb V. IL-7 and lymphopenia. Clin Chim Acta. 2011;412 (1–2):7–16. Epub 2010/09/21. doi: S0009-8981 (10) 00568-1 [pii] 10.1016/j.cca.2010.09.002. PubMed PMID: 20850425.

91.

Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res. 2010;70 (13):5249–58. Epub 2010/06/10. doi: 0008–5472. CAN-09-2860 [pii] 10.1158/0008-5472.CAN-09-2860. PubMed PMID: 20530666; PubMed Central PMCID: PMC2896454.

92.

Holm AM, Aukrust P, Damas JK, Muller F, Halvorsen B, Froland SS. Abnormal interleukin-7 function in common variable immunodeficiency. Blood. 2005;105 (7):2887–90. Epub 2004/12/16. doi: 2004-06-2423 [pii] 10.1182/blood-2004-06-2423. PubMed PMID: 15598813.

93.

Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH. TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol. 1997;159(1):117–25.PubMed

94.

Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929–79. doi:10.1146/annurev.immunol.22.012703.104622.PubMed

95.

Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890–3.PubMedCentralPubMed

96.

Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546–58. doi:10.1016/j.immuni.2008.02.017.PubMed

97.

Fevang B, Yndestad A, Sandberg WJ, Holm AM, Muller F, Aukrust P, et al. Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol. 2007;147(3):521–5. doi:10.1111/j.1365-2249.2006.03314.x.PubMedCentralPubMed

98.

Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143(2):347–55. doi:10.1053/j.gastro.2012.04.045.PubMed

99.

Zhou Z, Huang R, Danon M, Mayer L, Cunningham-Rundles C. IL-10 production in common variable immunodeficiency. Clin Immunol Immunopathol. 1998;86 (3):298–304. Epub 1998/04/29. doi: S0090122997944834 [pii]. PubMed PMID: 9557163.

100.

Kasztalska K, Ciebiada M, Cebula-Obrzut B, Gorski P. Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clinical drug investigation. 2011;31(5):299–307. doi: 10.2165/11586710-000000000-00000. PubMed PMID: 21473654

101.

Rezaei N, Aghamohammadi A, Mahmoudi M, Shakiba Y, Kardar GA, Mahmoudi M, et al. Association of IL-4 and IL-10 gene promoter polymorphisms with common variable immunodeficiency. Immunobiology. 2010;215(1):81–7. doi:10.1016/j.imbio.2009.01.011.PubMed

102.

Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547–9.PubMed

103.

Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med. 1995;181(2):817–21.PubMed

104.

Smith T, Hewson AK, Kingsley CI, Leonard JP, Cuzner ML. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol. 1997;150(6):1909–17.PubMedCentralPubMed

105.

Cambronero R, Sewell WA, North ME, Webster AD, Farrant J. Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency. J Immunol. 2000;164(1):488–94.PubMed

106.

Martinez-Pomar N, Raga S, Ferrer J, Pons J, Munoz-Saa I, Julia MR, et al. Elevated serum interleukin (IL)-12p40 levels in common variable immunodeficiency disease and decreased peripheral blood dendritic cells: analysis of IL-12p40 and interferon-gamma gene. Clin Exp Immunol. 2006;144(2):233–8. doi:10.1111/j.1365-2249.2006.03063.x.PubMedCentralPubMed

107.

McQuaid A, Tormey VJ, Trafford B, Webster AD, Bofill M. Evidence for increased expression of regulatory cytokine receptors interleukin-12R and interleukin-18R in common variable immunodeficiency. Clin Exp Immunol. 2003;134(2):321–7.PubMedCentralPubMed

108.

Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs. 2007;10(1):53–9. Epub 2006/12/26. PubMed PMID: 17187316

109.

Cunningham-Rundles C, Radigan L. Deficient IL-12 and dendritic cell function in common variable immune deficiency. Clin Immunol. 2005;115 (2):147–53. Epub 2005/05/12. doi: S1521-6616 (04) 00373-0 [pii] 10.1016/j.clim.2004.12.007. PubMed PMID: 15885637.

110.

Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med. 2002;196(7):969–77.PubMedCentralPubMed

111.

Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007;282 (48):34605–10. Epub 2007/09/22. doi: M705100200 [pii] 10.1074/jbc.M705100200. PubMed PMID: 17884812; PubMed Central PMCID: PMC2323680.

112.

Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57–63. doi:10.1038/35040504.PubMed

113.

Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol. 2007;179 (9):5886–96. Epub 2007/10/20. doi: 179/9/5886 [pii]. PubMed PMID: 17947662.

114.

Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science. 2002;298 (5598):1630–4. Epub 2002/11/26. doi: 10.1126/science.1077002 298/5598/1630 [pii]. PubMed PMID: 12446913.

115.

Kotlarz D, Zietara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med. 2013;210(3):433–43. doi:10.1084/jem.20111229.PubMedCentralPubMed

116.

de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. The Journal of biological chemistry. 2007;282(28):20053–7. doi: 10.1074/jbc.R700006200. PubMed PMID: 17502368

117.

de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69(6):912–20.PubMed

118.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84. doi:10.1038/ni.1863.PubMed

119.

Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. The Journal of general virology. 2000;81(Pt 10):2341–64. PubMed PMID: 10993923

120.

Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461–70.PubMed

121.

Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010;6(1):40–9. doi:10.1038/nrrheum.2009.237.PubMedCentralPubMed

122.

Strannegard O, Bjorkander J, Hellstrand K, Pacsa A, Hermodsson S, Hanson LA. Interferon and beta 2-microglobulin in patients with common variable immunodeficiency or selective IgA deficiency. International archives of allergy and applied immunology. 1987;84(3):217–22. PubMed PMID: 2443457

123.

Yu JE, Knight AK, Radigan L, Marron TU, Zhang L, Sanchez-Ramon S, et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. The Journal of allergy and clinical immunology. 2009;124 (2):349–56, 56 e1-3. doi: 10.1016/j.jaci.2009.05.019. PubMed PMID: 19592080; PubMed Central PMCID: PMC2908501.

124.

Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature. 1982;298(5877):859–63.PubMed

125.

Hauber I, Fischer MB, Eibl MM. Patients with common variable immunodeficiency (CVID) display aberrant IL-2 and IFN-gamma mRNA levels. Immunodeficiency. 1993;4(1–4):25–9.PubMed

126.

Serrano D, Becker K, Cunningham-Rundles C, Mayer L. Characterization of the T cell receptor repertoire in patients with common variable immunodeficiency: oligoclonal expansion of CD8 (+) T cells. Clin Immunol. 2000;97(3):248–58. doi:10.1006/clim.2000.4941.PubMed

127.

North ME, Ivory K, Funauchi M, Webster AD, Lane AC, Farrant J. Intracellular cytokine production by human CD4+ and CD8+ T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry. Clin Exp Immunol. 1996;105(3):517–22.PubMedCentralPubMed

128.

Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163–96. Epub 2001/03/13. doi: 19/1/163 [pii] 10.1146/annurev.immunol.19.1.163. PubMed PMID: 11244034.

129.

Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol. 2007;7 (3):279–82. Epub 2007/05/04. doi: S1471-4892 (07) 00063-X [pii] 10.1016/j.coph.2007.03.001. PubMed PMID: 17475560.

130.

Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68 (10):930–41. Epub 2010/08/10. doi: S0006-3223 (10) 00601-3 [pii] 10.1016/j.biopsych.2010.06.012. PubMed PMID: 20692646.

131.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67 (5):446–57. Epub 2009/12/18. doi: S0006-3223 (09) 01229-3 [pii] 10.1016/j.biopsych.2009.09.033. PubMed PMID: 20015486.

132.

Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51(1):37–43.PubMedCentralPubMed

133.

Chatzantoni K, Mouzaki A. Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr Top Med Chem. 2006;6(16):1707–14.PubMed

134.

Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol. 2006;6 (1):43–50. Epub 2006/03/01. doi: 10.1097/01.all.0000199798.10047.74 00130832-200602000-00009 [pii]. PubMed PMID: 16505611.

135.

Aukrust P, Lien E, Kristoffersen AK, Muller F, Haug CJ, Espevik T, et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency–possible immunologic and clinical consequences. Blood. 1996;87(2):674–81.PubMed

136.

Chua I, Standish R, Lear S, Harbord M, Eren E, Raeiszadeh M, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2007;150 (2):306–11. Epub 2007/09/08. doi: CEI3481 [pii] 10.1111/j.1365-2249.2007.03481.x. PubMed PMID: 17822445; PubMed Central PMCID: PMC2219360.

137.

Hatab AZ, Ballas ZK. Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. The Journal of allergy and clinical immunology. 2005;116(5):1161–2. doi: 10.1016/j.jaci.2005.08.041. PubMed PMID: 16275393

138.

Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005;95 (3):293–300. Epub 2005/10/05. doi: S1081-1206 (10) 61228-8 [pii] 10.1016/S1081-1206(10)61228-8. PubMed PMID: 16200822.

139.

Barbosa RR, Silva SP, Silva SL, Melo AC, Pedro E, Barbosa MP, et al. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One. 2011;6(8):e22848. doi:10.1371/journal.pone.0022848.PubMedCentralPubMed

140.

Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67. doi:10.1016/j.immuni.2008.03.004.PubMedCentralPubMed

141.

Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6 (2):R120-8. Epub 2004/04/03. doi: 10.1186/ar1038 ar1038 [pii]. PubMed PMID: 15059275; PubMed Central PMCID: PMC400429.

142.

Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218–22. doi:10.1172/JCI28508.PubMedCentralPubMed

143.

Mannon PJ, Fuss IJ, Dill S, Friend J, Groden C, Hornung R, et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 2006;131 (3):748–56. Epub 2006/09/06. doi: S0016-5085 (06) 01311-4 [pii] 10.1053/j.gastro.2006.06.022. PubMed PMID: 16952544.

144.

Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24(3):203–15. doi:10.1016/j.cytogfr.2013.04.003.PubMed

145.

Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820–8. doi:10.1038/ng1600.PubMed

146.

Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–56.PubMedCentralPubMed

147.

Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465–75. doi:10.1038/nri844.PubMed

148.

Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005;174(9):5537–44.PubMed

149.

Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005;115(11):3083–92. doi:10.1172/JCI25265.PubMedCentralPubMed

150.

Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006;54(1):192–201. doi:10.1002/art.21526.PubMed

151.

Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15(9):570–6.PubMed

152.

Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829–34. doi:10.1038/ng1601.PubMed

153.

Losi CG, Salzer U, Gatta R, Lougaris V, Cattaneo G, Meini A, et al. Mutational analysis of human BLyS in patients with common variable immunodeficiency. J Clin Immunol. 2006;26(4):396–9. doi:10.1007/s10875-006-9026-2.PubMed

154.

Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol. 2007;124(2):182–9. doi:10.1016/j.clim.2007.04.012.PubMedCentralPubMed

155.

Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, et al. Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency. International journal of molecular medicine. 2008;21(2):233–8. PubMed PMID: 18204790

156.

Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012;188(1):497–503. doi:10.4049/jimmunol.1102321.PubMed

157.

Fischer MB, Hauber I, Eggenbauer H, Thon V, Vogel E, Schaffer E, et al. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood. 1994;84(12):4234–41.PubMed

158.

Koval'chuk LV, Khoreva MV, Varivoda AS, Pashchenko OE, Gracheva LA, Bykova LP, et al. Analysis of toll-like receptor-dependent production of proinflammatory cytokines in vitro by human peripheral blood mononuclears of donors and patients with primary immunodeficiency. Bull Exp Biol Med. 2007;144(1):63–5. PubMed PMID: 18256754.PubMed

159.

Pandolfi F, Paganelli R, Oliva A, Quinti I, Polidori V, Fanales-Belasio E, et al. Increased IL-6 gene expression and production in patients with common variable immunodeficiency. Clin Exp Immunol. 1993;92(2):239–44.PubMedCentralPubMed

160.

Junker U, vd Heyden-Rynsch B, Diener C, Vogelsang H, Jager L. In patients with common variable immunodeficiency, interleukin-6 and expression of its receptor on B-cells are normal. Cell Biol Int. 1993;17 (6):609–14. Epub 1993/06/01. doi: S1065699583711066 [pii]. PubMed PMID: 8348119.

161.

Rezaei N, Aghamohammadi A, Nourizadeh M, Kardar GA, Pourpak Z, Zare A, et al. Cytokine production by activated T cells in common variable immunodeficiency. Journal of investigational allergology & clinical immunology. 2010;20(3):244–51. PubMed PMID: 20635790

162.

Pastorelli G, Roncarolo MG, Touraine JL, Rousset F, Pene J, de Vries JE. Interleukin-4 suppresses immunoglobulin production by peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) induced by supernatants of T cell clones. Clin Exp Immunol. 1989;78(3):341–7.PubMedCentralPubMed

163.

Clemente A, Pons J, Lanio N, Matamoros N, Ferrer JM. CD27 (+) B cells from a subgroup of common variable immunodeficiency patients are less sensitive to apoptosis rescue regardless of interleukin-21 signalling. Clin Exp Immunol. 2013;174(1):97–108. doi:10.1111/cei.12150.PubMed

Title: Cytokines in Common Variable Immunodeficiency as Signs of Immune Dysregulation and Potential Therapeutic Targets – A Review of the Current Knowledge
Authors: Farnaz Najmi Varzaneh
Bärbel Keller
Susanne Unger
Asghar Aghamohammadi
Klaus Warnatz
Nima Rezaei
Publication date: 01-07-2014
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 5/2014
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-014-0053-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Elevated Double Negative T Cells in Pediatric Autoimmunity

Erratum to: Intact IFN-γR1 Expression and Function Distinguishes Langerhans Cell Histiocytosis From Mendelian Susceptibility to Mycobacterial Disease

Clinical and Genetic Characterization of Japanese Sporadic Cases of Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis Syndrome from a Single Medical Center in Japan

Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia

The Effects of Bruton Tyrosine Kinase Inhibition on Chemotaxis and Superoxide Generation in Human Neutrophils

RAG1 Reversion Mosaicism in a Patient with Omenn Syndrome

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage